Shashikala Venkatachalapathy, MD
Psychiatry · Salisbury, MDNPI 1669555462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 565 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 565 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$913
- Lundbeck LLC$853
- Otsuka America Pharmaceutical, Inc.$814
- plus $5K from 23 others
What the payments were for
- Food & beverage$10,92498%
- Education$2352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 106 | $1,352 |
| AbbVie(2 entities) | 77 | $1,281 |
| Alkermes, Inc. | 41 | $1,046 |
| Teva Pharmaceuticals USA, Inc. | 40 | $913 |
| Lundbeck LLC | 48 | $853 |
| Otsuka America Pharmaceutical, Inc. | 40 | $814 |
| Vanda Pharmaceuticals Inc. | 23 | $708 |
| Sunovion Pharmaceuticals Inc. | 29 | $659 |
| Johnson & Johnson | 30 | $618 |
| E.r. Squibb & Sons, L.L.C. | 18 | $567 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $477 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $463 |
| Axsome Therapeutics, Inc. | 12 | $373 |
| Indivior Inc. | 11 | $200 |
| Idorsia Pharmaceuticals US Inc | 8 | $180 |
| Exact Sciences | 7 | $154 |
| Boehringer Ingelheim | 1 | $111 |
| Eisai Inc. | 5 | $93 |
| Novo Nordisk | 4 | $73 |
| Abbott | 2 | $41 |
| Pfizer | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $33 |
| Neuronetics, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Vertos Medical, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Tempus AI, Inc | 1 | $14 |
| Vistapharm, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- COBENFY$240
- LATUDA$125
- ARISTADA INITIO$125
- Fanapt$125
- INGREZZA$125
- Auvelity$120
- VRAYLAR$120
- INVEGA SUSTENNA$115
- JARDIANCE$111
How this compares
$11,160 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 86 | $733,726 |
| Austedo XrDeutetrabenazine | 27 | $195,728 |
| Invega SustennaPaliperidone Palmitate | 39 | $118,384 |
| VraylarCariprazine Hcl | 73 | $112,739 |
| UzedyRisperidone | 39 | $109,893 |
| AristadaAripiprazole Lauroxil | 24 | $74,808 |
| TrintellixVortioxetine Hydrobromide | 58 | $38,793 |
| Risperdal ConstaRisperidone Microspheres | 21 | $36,839 |
| RexultiBrexpiprazole | 20 | $31,267 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,853 |
| Lurasidone Hcl | 73 | $17,757 |
| Aripiprazole | 199 | $12,581 |
| Clozapine | 119 | $10,318 |
| Paliperidone ErPaliperidone | 50 | $9,493 |
| Quetiapine Fumarate | 309 | $7,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,352 | $733,72686 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $913 | $305,62166 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $618 | $155,22360 claims |
| AbbVieVraylar | $1,281 | $112,73973 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,046 | $97,66238 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $477 | $38,79358 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $814 | $31,26720 claims |
| Lilly USA, LLCOlanzapine | $15 | $2,447118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Salisbury
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.